ELIAS Animal Health

Exploring New Frontiers in Cancer Therapy with Oncolytic Virotherapy ELIAS Animal Health is advancing veterinary oncology by developing innovative immunotherapy options using oncolytic viruses. This cutting-edge approach offers several promising benefits: 🔍 Precisely targets and attacks cancer cells, while leaving healthy cells unharmed. 🩸 Enhances the immune system's response to fight cancer more effectively. 💪 Potentially reduces the side effects typically associated with conventional cancer treatments. 🦠 Utilizes specially engineered viruses that specifically infect and destroy cancer cells. We are excited about the potential of oncolytic virotherapy to transform cancer treatment in veterinary medicine! #ELIAS #CancerTreatment #Innovation #VeterinaryOncology

Bridging Human and Pet Health At ELIAS Animal Health, our mission is inspired by the advances in human cancer treatments, and we're dedicated to translating these breakthroughs to veterinary care. Our journey began with the goal to not only innovate in the pet health space but also to contribute to human oncology through collaborative research. Explore how our partnerships with human health companies are fostering a mutual exchange of knowledge, and enhancing cancer therapies for both humans and pets. Together, we're committed to developing safer and more effective treatments that benefit everyone in our community. https://lnkd.in/gvTfPrUQ #ELIAS #CancerResearch #PetHealth

T Cell Immunotherapy for Canine Cancer At ELIAS Animal Health, we are pioneering a novel approach to combat canine cancer with our ELIAS Cancer Immunotherapy (ECI®), an adoptive T cell therapy that stimulates a patient’s immune system to recognize and attack cancers. ECI® uses a personalized vaccine made from a patient’s own cancer cells to “prime” the immune cells to recognize the cancer. These primed immune cells—which are collected from the patient through a procedure called apheresis—are activated and expanded 𝘦𝘹 𝘷𝘪𝘷𝘰 for reinfusion into the patient, where they travel to the cancer cells and attack them. Our commitment to advancing veterinary medicine through cutting-edge therapies like ECI® demonstrates our dedication to improving the lives of pets and comforting their owners. Join us on this journey to redefine cancer treatment in veterinary care. #VeterinaryOncology #CanineCancer #InnovativeTherapy #TCellImmunotherapy #ELIAS

Question: How does ECI® work? Answer: Cancer has many ways to hide from the patient’s immune system, which prevents the immune system from eliminating it. The ELIAS Cancer Immunotherapy (ECI®) works by stimulating the patient’s immune system to recognize cancer cells as “foreign” and subsequently eliminate them. #ELIAS #ECI #Cancer #CanineCancer #CancerTreatment #CureCancer

As part of our commitment to improving outcomes in veterinary cancer patients through the advancement of innovative therapies, we're thrilled to announce this capacity expansion. In addition to accommodating increased demand for ECI® after commercial launch later this year, the new manufacturing facility will enable ELIAS to continue development work on our pipeline of innovation.

At #ELIAS Animal Health, our mission is to revolutionize the treatment of canine cancer. We're harnessing the power of immunotherapy to stimulate the body's defenses against cancer, providing more promising options for pets and their families. Discover how we're making a difference: https://lnkd.in/gW_7Qr7H #ELIAS #CanineCancer #CancerTreatment #Immunotherapy

This Earth Day, we reflect on the interconnectedness of all living beings. At ELIAS Animal Health, we recognize the impact of veterinary health on our ecosystem. Let's honor our planet by ensuring the health and well-being of every creature that calls it home. #ELIAS #EarthDay2024 #OneHealth #VeterinaryCare

The National Cancer Institute (NCI) Center for Cancer Research recently highlighted the value of learning from our pets' experiences with cancer in its “Milestones 2024” report. One article discussed how understanding the similarities between human and canine osteosarcoma can provide valuable insights and accelerate progress on both sides. ELIAS was founded to expand and accelerate the progress already made in fighting human cancers by applying the technology to fight cancer in dogs and other companion animals through strategic collaborations with human health companies. One notable collaboration was TVAX Biomedical, Inc.'s FDA Fast Track Designation, in which the efficacy and safety data from ELIAS’s canine osteosarcoma pilot study was an important component of the Fast Track application. #comparativeoncology

Podcast Alert! 🎙️ We are honored to have been a recent guest on Biotechnology Innovation Organization's podcast. Discover our inspiring journey with a mission to transform veterinary oncology. In the US alone, six million dogs are diagnosed with cancer annually, with only three and a half million receiving specialized treatment. Dive into the world of innovative cancer therapeutics and how we are addressing this critical medical need. 🐾 Tune in to the full podcast episode available on all major platforms, including Apple Podcasts, Spotify, and Simplecast, to learn more about our efforts in fighting canine cancer and bringing hope to millions of pets and their families. #ELIAS #Podcast #IAmBio #AnimalHealth #FightCanineCancer #CancerTreatment

This recent article from the American Animal Hospital Association (AAHA) discusses how ECI® targets cancer cells in a dog's body. Find out how our personalized, two-step approach amplifies a dog's own immune system to fight its cancer. #dogcancer #cancerimmunotherapy